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Abstract
Introduction: Parathyroid carcinoma represents a rare cause of primary 
hyperparathyroidism. Distinguishing carcinoma from the benign tumors underlying 
primary hyperparathyroidism remains challenging. The diagnostic criteria for 
parathyroid carcinoma are local and/or metastatic spreading. Atypical parathyroid 
adenomas share other histological features with carcinomas but lack invasive growth. 
Somatostatin receptors are commonly expressed in different neuroendocrine tumors, 
but whether this also holds for parathyroid tumors remains unknown.
Aim: Our aim is to examine the immunohistochemical expression of somatostatin 
receptor 1–5 in parathyroid typical adenomas, atypical adenomas and carcinomas.
Methods: We used a tissue microarray construct from a nationwide cohort of parathyroid 
carcinomas (n = 32), age- and gender-matched typical parathyroid adenomas (n = 72) 
and atypical parathyroid adenomas (n = 27) for immunohistochemistry of somatostatin 
receptor subtypes 1–5. We separately assessed cytoplasmic, membrane and nuclear 
expression and also investigated the associations with histological, biochemical and 
clinical characteristics.
Results: All parathyroid tumor subgroups expressed somatostatin receptors, although 
membrane expression appeared negligible. Except for somatostatin receptor 1, 
expression patterns differed between the three tumor types. Adenomas exhibited the 
weakest and carcinomas the strongest expression of somatostatin receptor 2, 3, 4 and 5. 
We observed the largest difference for cytoplasmic somatostatin receptor 5 expression.
Conclusions: Parathyroid adenomas, atypical adenomas and carcinomas all express 
somatostatin receptor subtypes 1–5. Somatostatin receptor 5 may serve as a potential 
tumor marker for malignancy. Studies exploring the role of somatostatin receptor imaging 
and receptor-specific therapies in patients with parathyroid carcinomas are needed.
Introduction
Primary hyperparathyroidism (PHPT) is a common 
endocrine disease usually caused by a parathyroid 
adenoma (in 85% of cases) or by glandular hyperplasia 
(15% of cases). Parathyroid carcinoma is only rarely the 
underlying cause (PC; about ~1% of PHPT). Symptoms 
of PC are related to the high serum calcium caused by 
the increased parathormone production and are the same 
but often more severe than those accompanying benign 
forms of PHPT. Furthermore, PC is very rare and difficult 
to diagnose, with no specific evidence-based treatment 
available (1, 2, 3, 4). Radical surgery is the only known 
potential cure for PC, while recurrence affects 20–60% of 
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patients (5, 6, 7, 8). Furthermore, recent studies reported 
an increasing incidence of PC in Australia, the USA and 
Europe (8, 9, 10), although the reasons for this increase 
remain unknown. The diagnostic criteria of PC are based on 
histological examination demonstrating invasive tumor 
growth or evidence of metastatic disease (11). Similarly, 
atypical adenomas (APAs) share some histopathological 
features with PC, such as a fibrous septae and intratumoral 
hemorrhage, although lacking invasive growth (11). 
Biochemically severe PHPT might raise the suspicion of 
malignant disease before surgery. However, there are no 
disease-specific preoperative markers for PC, and it is 
nearly impossible to render a preoperative diagnosis of 
PC if the patient has no signs of metastatic disease. Some 
immunohistochemical markers indicating aggressive 
tumor behavior in PC and APA exist, such as a high Ki-67 
percentage (>5%) (2, 12). A negative parafibromin stain 
is present in up to 75% of sporadic PCs, but rarely in 
adenomas (13, 14). Parafibromin is encoded by CDC73, 
a tumor suppressor gene. Germline mutations of CDC73 
lead to the loss of parafibromin expression and are 
associated with a high risk of PC (15, 16). CDC73 germline 
mutations underlie the hyperparathyroidism jaw-tumor 
syndrome (HPT-JT), characterized by early-onset PHPT, 
ossifying jaw fibromas, kidney and uterine tumors, but 
may also cause familial isolated hyperparathyroidism 
(15, 16, 17). Parafibromin immunohistochemistry is 
thus a useful marker. The specificity of negative staining 
is high (18) and prompts genetic studies, that is search 
for CDC73 germline mutations and genetic counseling, 
as appropriate. However, there are exceptions and more 
than 20% of PC cases stain positive for parafibromin on 
immunohistochemistry.
Somatostatin receptors (SSTs) mediate the effects of 
the hormone somatostatin. These membrane-bound 
G-protein-coupled receptors mediate their effects by 
altering the levels of intracellular calcium and cAMP. 
They may also heterodimerize with each other, as well as 
with β-adrenergic and opioid receptors, which, depending 
on the receptor type, can inhibit or enhance the effects 
of SST. There are five known SST subtypes: SST1, SST2, 
SST3, SST4 and SST5. Through alternative splicing, two 
variants of SST2 (SST2a and SST2b) exist. Moreover, SSTs 
can be found throughout the body with differing subtype 
distributions in various organs and tissues: in the central 
nervous system, the gastrointestinal tract, the pancreas 
and the kidneys as well as in leukocytes, endothelial cells 
and macrophages (19).
Somatostatin analogs are widely used in the 
treatment of different neuroendocrine tumors, such as 
ACTH-producing pituitary adenomas, somatotropinomas 
and gastropancreatic neuroendocrine neoplasms. They 
not only suppress hormonal hypersecretion by binding 
to different SSTs, but also have an antiproliferative effect 
on tumor cells (20). The somatostatin analog octreotide as 
well as peptide receptor-based radiotherapy, both of which 
primarily target SST2, have been used in the treatment of 
PTH-related protein (PTHrP)-dependent hypercalcemia 
caused by metastatic gastroenteropancreatic 
neuroendocrine tumors. As such, diminished calcium 
and PTHrP concentrations as well as stable disease were 
achieved in some patients (21). A previous study found 
somatostatin receptors 1, 3 and 4 expression in normal 
parathyroid cells (22). No previous studies on the 
expression of SSTs in neoplastic parathyroid tissue appear 
in the literature.
Therefore, we aimed to investigate the expression 
profile of somatostatin receptor subtypes in different 
parathyroid tumors underlying PHPT in a large 
patient cohort. We also sought to determine whether 
SSTs could serve as tumor markers in the differential 
diagnosis of typical parathyroid adenomas, atypical 
adenomas and carcinomas, perhaps as additive PC 
immunohistochemistry panel markers to the previously 
established parafibromin, Ki-67, galectin 3 and protein 
gene product 9.5 (PGP9.5) (15).
Materials and methods
Tumor material and patient cohort
Our material comprised 132 tumor samples from 
three tissue subgroups: parathyroid carcinomas (PCs), 
atypical parathyroid adenomas (APAs) and parathyroid 
adenomas (PAs).
The PC group consisted of tissue specimens from all 
patients diagnosed with PC in Finland between 2000 and 
2011 (n = 32) (8). The PC patients were identified from the 
Finnish Cancer Registry using the ICD-10 code (C75.0) 
and from the databases of the five Finnish university 
hospitals and eight Finnish central hospitals, including 
their pathology databases.
Both the APA patients (n = 27) and the PA patients 
(n = 72) were retrieved from the Helsinki University 
Hospital pathology database (HUSLAB). The APA group 
(n = 27) consisted of a consecutive cohort diagnosed 
between 2000 and 2011. The PA patients were age and 
gender matched with the PC group. All PHPT patients with 
APAs and PAs were treated in the Endocrine Department 
at the Helsinki University Hospital.
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Clinical data as well as the basic immunohistochemical 
characteristics of the tumors were described previously 
(8). Briefly, six PC patients had metastatic disease and two 
had local recurrence. None of the patients had MEN1. 
More information on the PC group appears in Table 1.
The Ethics Committee of Helsinki University Hospital 
approved the study protocol. Permission to use the 
histological specimens for this study without requiring 
individual informed consent was granted by the Finnish 
National Supervisory Authority for Welfare and Health 
(Valvira) (Dnro 8031/06.01.03.01/2015).
Tissue microarray
The tissue microarray (TMA) blocks were created as 
described previously. Briefly, the most representative 
tumor blocks were chosen and six 1.0 mm cores from PC 
and APA samples, and three cores for PAs were punched 
for the TMA blocks, representing both the tumor border 
and central areas (8).
Immunohistochemistry
Tissue sections (3.5 μm) were cut using a microtome. 
Heat-induced antigen retrieval was performed after 
deparaffinization using xylene and graded alcohol series. 
Sections were incubated using primary antibodies. 
Table 2 summarizes information on the antibodies 
used as well as the staining details. These antibodies 
have previously been used by our research group also 
including negative controls (23), and their specificity 
have been confirmed by Western blot and in vitro receptor 
autoradiography (24, 25, 26, 27, 28). Antibody binding 
was visualized using the polymer-based OptiView and 
UltraView Universal DAB Detection Kit (Ventana Medical 
System, Inc., Tucson, AZ, USA) or the EnVision Detection 
Systems (Dako, Agilent Pathology Solutions). Automated 
(Benchmark Ultra, Ventana) or semi-automated 
(AutoStainer, Lab Vision Corp., Fremont, CA, USA) 
staining instruments were used. Mayer’s hematoxylin 
(Dako) was used for the counterstaining on all slides. In 
addition, intestinal mucosa and Langerhans’ islet cells 
were used as positive controls. Normal parathyroid tissue 
was stained using SST antibodies for comparison.
Scoring
The immunohistochemical scoring was done 
independently by two researchers (SS and HL), without 
knowledge of the nature of the tumors. For any 
disagreements, the score was determined by reaching 
consensus following a discussion of the case. Staining was 
assessed separately for cytoplasmic (C), nuclear (N) and 
membranous (M) staining. Examples of representative 
SST stainings appear in Fig. 1. Staining was considered 
positive if at least 1% of the tumor cells per spot was 
stained. The intensity of the staining was estimated using 
a score of 0 to 3, where 0 represented completely negative 
and 3 represented as intense staining as in the positive 
control tissue. For each tumor, the TMA spot with the 
strongest staining intensity was used in the statistical 
analyses. Overall, the staining intensity was weak, and 
the intensity was not taken into account in the primary 
analyses, that is, TMA spots were only considered 
positive or negative. Scoring was carried out using 10× 
and 20× magnification for SST2, SST3 and SST4. The slides 
stained with antibodies for SST1 and SST5 were digitized 
using a panoramic scanner (3DHISTECH) and scoring 
was performed on digitized slides using the CaseViewer 
software (3DHISTECH), also relying on 10× and 
20× magnifications.
Table 1 Characteristics of patients with parathyroid 
carcinoma. Numbers are presented as median (range).
Number of patients 32
Age at diagnosis (years) 64 (35–83)
Preoperative serum ionized calcium (mmol/L) 1.76 (1.38–2.58)
Preoperative PTH (ng/L) 989 (68–4000)
Ki-67% 5 (0–40)
Patients with metastatic disease or local 
recurrence
7
Disease-related death 5
Table 2 Antibodies and staining protocols used.
Receptor Clone Epitope sequence Antibody Company Dilution Dilution time
SSTR1 UMB-7 ENLESGGVFRNGTCTSRITTL Ab137083 Abcam 1:500 45 min
SSTR2 UMB-1 ETQRTLLNGDLQTSI Ab134152 Abcam 1:300 32 min
SSTR3 UMB-5 QLLPQEASTGEKSSTMRISYL Ab137026 Abcam 1:7000 60 min
SSTR4 Sstr4 CQQEALQPEPGRKRIPLT MCA5922 AbD Serotec 1:500 30 min
SSTR5 UMB-4 QEATPPAHRAAANGLMQTSKL Ab109495 Abcam 1:1000 30 min
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Statistical analysis
We used IBM SPSS Statistics version 23 (SPSS, Inc.) and 
RStudio version 1.0.153 (RStudio, Inc.) software for all 
statistical analyses and data processing. We considered 
P < 0.05 (two-tailed) as statistically significant. We used 
the χ2 test and the Fisher’s exact test, as appropriate, 
to investigate the relationships between categorical 
parameters. The Mann–Whitney U test was used for 
continuous variables.
Results
All SST subtypes were to some degree expressed in 
parathyroid tumors. Normal parathyroid tissue (n = 6) was 
negative, except for some weak, diffuse cytoplasmic SST5 
staining in four of six tissue samples. Cytoplasmic SST1 
and SST5 were the most abundantly expressed SST subtypes 
in parathyroid tumors. Yet, membrane expression was 
negligible in all receptor subtypes and was, therefore, 
excluded from comparisons. Individual tumors, however, 
were of particular interest. Detailed information regarding 
SST expression appears in Fig. 2 and Table 3.
Somatostatin receptor 1 (SST1)
Membrane expression was absent for all tumor subtypes. 
Yet, both nuclear and cytoplasmic expression of SST1 was 
present, although expression did not differ significantly 
between the three tumor subgroups.
Somatostatin receptor 2 (SST2)
Cytoplasmic staining was most prevalent in carcinomas 
and less so in APA and PA (P = 0.01). However, staining was 
scarce for all tumor subtypes. Interestingly, membrane 
positivity was found in only two carcinomas.
Somatostatin receptor 3 (SST3)
Cytoplasmic expression was weak and did not differ 
between the tumor subgroups. As with SST2, we found 
two SST3 membrane-positive carcinomas. These were 
not the same tumors that demonstrated SST2 membrane 
positivity. The nuclear expression of SST3 in the PC group 
was increased, compared to the expression in the APA and 
PA subgroups (P < 0.001).
Somatostatin receptor 4 (SST4)
Both cytoplasmic and nuclear expression increased in PC 
compared to the other tumor groups (cytoplasmic P = 0.032; 
nuclear P = 0.009). Membranous expression occurred in 
a small number of tumors across all tumor subgroups, 
although the difference between groups was not significant.
Somatostatin receptor 5 (SST5)
The largest difference between groups was found in the 
expression of SST5. The cytoplasmic expression of SST5 
appeared weakest in PAs, intermediate in APAs and highest 
in PC, since nearly all carcinomas were positive (P < 0.001). 
The positive predictive value (PPV) of positive cytoplasmic 
Figure 1
Examples of the staining intensities in parathyroid tumor tissue for the scoring system used in our study for cytoplasmic and nuclear expression. 
Membrane expression was weak and the intensity was not sufficiently diverse to make a similar comparison. Left: negative staining (0). Subsequent: 
weak cytoplasmic and nuclear staining (1), strong cytoplasmic and nuclear staining (2) and very strong cytoplasmic and nuclear staining (3). On the right 
are pancreatic islets stained with SST1 and SST5 presenting cytoplasmic and membrane positivity, functioning as positive control. Nuclear positivity is not 
found in the control stainings.
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SST5 staining is 0.52, while the negative predictive value 
(NPV) of SST5 staining is 0.94. Furthermore, the nuclear 
expression differed significantly between subgroups 
(P = 0.043). Membrane SST5 staining was negative.
Association with other parameters
Table 4 summarizes the correlations between SST expression 
and other biomarkers. Only three of our PC tumors had 
negative parafibromin staining, and another 12 had 
diminished staining. Negative parafibromin staining was 
associated with cytoplasmic SST2 (P = 0.04) and nuclear SST3 
(P = 0.019) positivity. There was no association between 
expression of parafibromin and SST5 (P = 0.192).
A higher Ki-67 level was associated with the positive 
expression of cytoplasmic SST4 (P = 0.048) and SST5 
(P < 0.001) as well as the nuclear expression of SST3 and 
SST5 (P = 0.003 and P < 0.001, respectively). Tumor size 
was not related to the expression of any of SST subtypes. 
Yet, high preoperative serum-ionized calcium and PTH 
concentrations were both associated with the expression 
of cytoplasmic SST5 (P < 0.001 for both).
The role of somatostatin receptors in PCs
The expressions of SST5, SST2M and SST3M were examined 
in carcinomas exclusively. The expression patterns in 
relation to disease aggressiveness appear in Table 5.
We found that SST5C-negative carcinomas (n = 3) 
may be more aggressive than SST5C-positive carcinomas. 
One SST5C-negative PC patient died of disease, 
Figure 2
Distribution of the cytoplasmic and membranous 
SSTs in parathyroid carcinoma (PC), atypical 
parathyroid adenoma (APA) and benign 
parathyroid adenoma (PA). The Y axis represents 
the proportion of positively stained TMA spots.
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Table 3 Tumors staining positive for SSTR.
Receptor PC APA PA P value
SSTR1 C 13/32 9/27 30/72 0.512
SSTR1 N 17/32 18/27 50/72 0.269
SSTR2 C 7/32 5/27 3/72 0.01a
SSTR2 M 2/32 0 0
SSTR3 C 9/32 7/27 11/72 0.264
SSTR3 N 9/32 6/27 2/72 <0.001a
SSTR3 M 2/32 0 0
SSTR4 C 18/32 11/27 21/72 0.032a
SSTR4 N 20/32 14/27 23/72 0.009a
SSTR4 M 1/32 1/27 4/72 0.873
SSTR5 C 28/32 15/27 11/72 <0.001a
SSTR5 N 30/32 20/27 50/72 0.038a
aSignificant P values.
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and another had metastatic disease. The third presented 
with non-recurrent disease. The median circulating PTH 
concentrations (1187 ng/L vs 823 ng/L) and Ki-67 (13 
vs 7%) were higher in SST5C-negative PCs compared to 
SST5C-positive tumors, although this difference was not 
statistically significant (Mann–Whitney U).
We also examined membrane-positive tumors for 
SST2 and SST3 separately. One SST3M-positive PC patient 
died of disease. The other SST3M-positive tumor appeared 
SST5C-negative but was otherwise unremarkable. In 
addition, one SST2M-positive PC patient was also SST5C 
negative and died from the disease. The SST2M-positive 
tumor patients exhibited a slightly higher serum ionized 
calcium concentration than the remainder of the group 
(median 2.09 mg/L compared to 1.75 mg/L). The SST2M-
positive tumor patients were also characterized by higher 
Ki-67 (2 vs 5%). All differences between SST2M-positive 
tumors and the remainder of the PC group were not 
statistically significant.
Discussion
Here, we demonstrate that SSTs 1 through 5 are expressed 
in different parathyroid tumors, while SST5 is particularly 
abundant in PCs. Furthermore, we show that SST5 
expression correlates with the tumor Ki-67 proliferation 
index, as well as with the circulating calcium and PTH 
Table 4 SSTR expression for all tumor groups in relation to Ki-67, tumor size, s-Ca-ion and s-PTH expressed as median (range).
SSTR2C
Positive tumors Negative tumors P value
Ki-67 (%) 5.8 (0–30) 3.1 (0–40) 0.069
Tumor size (cm) 2.48 (1.0–4.0) 2.0 (1.0–5.0) 0.142
S-Ca-ion (mmol/L) 1.69 (1.38–2.42) 1.56 (1.28–2.58) 0.098
S-PTH (ng/l) 727 (34–2001) 514 (68–4000) 0.198
 
SSTR3N
Positive tumors Negative tumors P value
Ki-67 5.6 (0–20) 3.1 (0–40) 0.003a
Tumor size (cm) 2.54 (1.0–4.0) 2.0 (1–5) 0.09
S-Ca-ion (mmol/L) 1.63 (1.32–2.02) 1.56 (1.28–2.58) 0.107
S-PTH (ng/L) 1049 (147–2769) 461 (34–4000) 0.003a
SSTR4C
Positive tumors Negative tumors P value
Ki-67 4.1 (0–40) 3.1 (0–40) 0.048a
Tumor size (cm) 2.2 (1.0–5.0) 2.0 (1.0-5.0) 0.607
S-Ca-ion (mmol/L) 1.60 (1.29–2.58) 1.55 (128–2.42) 0.142
S-PTH (ng/L) 613 (68–4000) 485 (34–2220) 0.139
SSTR4N
Positive tumors Negative tumors P value
Ki-67 4.1 (0.40) 3.0 (0–30) 0.225
Tumor size (cm) 2.23 (1–5) 2.0 (1.0–4.0) 0.825
S-Ca-ion (mmol/L) 1.57 (1.29–2.04) 1.58 (128–2.58) 0.487
S-PTH (ng/L) 580 (34–2220) 500 (68–4000) 0.258
SSTR5C
Positive tumors Negative tumors P value
Ki-67 4.0 (0–40) 1.4 (0–30) <0.001a
Tumor size (cm) 2.20 (1.0–5.0) 2.0 (1.0–5.0) 0.135
S-Ca-ion (mmol/L) 1.68 (1.32–2.58) 1.45 (1.28–2.42) <0.001a
S-PTH (ng/L) 634 (34–4000) 173 (73–2210) <0.001a
SSTR5N
Positive tumors Negative tumors P value
Ki-67 0.0 (0–40) 0.0 (0–10) 0.267
Tumor size (cm) 2.0 (1.0–5.0) 2.0 (1.0–4.0) 0.079
S-Ca-ion (mmol/L) 1.52 (1.28–2.58) 1.45 (1.29–1.85) 0.141
S-PTH(ng/L) 264 (34–4000) 188 (77–2220) 0.230
aSignificant P values.
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concentrations. In addition, the expression of cytoplasmic 
SST2, SST4 and SST5 as well as nuclear SST3, SST4 and SST5 
consistently mirror the lowest expressions in adenomas, 
the intermediate expression in atypical adenomas and 
the highest expression in carcinomas. While membrane 
positivity is very seldom detectable, four PCs showed 
membrane positivity either for SST2 or SST3, suggesting 
that SST2- and SST3-targeted imaging and therapies could 
potentially improve the management of these patients.
Taniyama et  al. demonstrated the expression of 
SST1, SST3 and SST4 (and to some degree SST5) expression 
in chief cells of normal parathyroid tissue using 
immunohistochemistry relying on polyclonal antibodies 
(22). We used monoclonal antibodies, demonstrating 
scarce expression of SST5 in normal parathyroid cells; but, 
in contrast to Taniyama et  al., we could not detect the 
expression of SST1, SST3 or SST4 in normal parathyroid 
tissue. To our knowledge, our study represents the first 
on SST expression in neoplastic parathyroid tissue. 
SST expression was lowest in adenomas and highest in 
carcinomas, with atypical adenomas falling in between. 
Negative SST stainings for normal parathyroid tissue fit 
with the pattern of an increased SST expression and an 
increasing neoplasticity.
The expression of somatostatin receptors carries 
a prognostic role in other neuroendocrine tumors. 
In gastroenteropancreatic NETs (GEP-NETs), SSTs are 
generally overexpressed in well-differentiated tumors 
with a decreasing expression in dedifferentiated tumors 
(29). In GEP-NETs, SST2 is the most frequently expressed 
receptor (30). The presence of SST5 and the absence of 
SST2 correlate with metastasis, angioinvasion and tumor 
growth (31). In pancreatic NETs, the low expression of 
SST2 and SST5 associates with a worse disease prognosis 
(32). When analyzing the PC group exclusively, we 
found that SST5C-negative carcinomas appeared to have 
higher calcium and PTH levels than the entire PC group 
average. These parameters previously investigated in our 
cohort strongly correlated with the nature of the tumor. 
Thus, the association between these parameters and SST 
expression is biased given that all these factors correlate 
with malignancy (8). Furthermore, the number of PCs 
with an adverse outcome is small.
The antibodies used in our study have been previously 
used and verified (25, 26, 27, 28, 33) with Western blotting 
and/or in vitro somatostatin receptor autoradiography. 
The same antibodies have previously been used by our 
research group for a study on pulmonary carcinoid tumors 
(23) as well as pheochromocytomas and paragangliomas 
(antibodies for SST2-SST4 (34)). We stained control 
tissue (pancreas and small intestine) to serve as a test 
for the functionality of the staining protocol as well as 
internal negative control. The Langerhans’ islet cells and 
enteroendocrine cells stained positive appropriate to the 
SST antibody used, while the surrounding tissue remained 
negative. Thus, one can assume that the staining we 
have observed is, in fact, valid also regarding the nuclear 
expression of SSTs.
In general, somatostatin receptors are considered 
membrane-bound G-protein-coupled receptors 
(35), with some degree of cytoplasmic staining on 
immunohistochemistry. We found that the membrane 
expression of SSTs were both faint and scarce. Ligand binding 
to somatostatin receptors induces receptor internalization 
by endocytosis for the lysosomal regrading or recycling of 
the receptor to the plasma membrane (36, 37). This could 
represent one mechanism explaining the cytoplasmic 
SST staining. Previous studies indicate that antibodies for 
SST2 generally stain the plasma membrane, while SST1, 
SST3 and SST5 stain the cytoplasm (38). Furthermore, 
SST expression generally decreases with a higher tumor 
grade as demonstrated in different NETs including 
pituitary adenomas, GEP-NETs, pheochromocytomas and 
paragangliomas, neuroblastoma, Merkel cell carcinoma 
and medullary thyroid carcinoma (38). Most previous 
studies have focused on membrane expression. We 
recently demonstrated that in pheochromocytomas and 
paragangliomas SST1–5 expression is either predominantly 
membranous (SST2) or cytoplasmic (SST1, 3–5) (34). In the 
present study, nuclear and cytoplasmic SST expression 
appeared in the majority of parathyroid tumors, with 
significantly different expression profiles in adenomas, 
atypical adenomas and carcinomas. The nuclear 
expression of somatostatin receptors is scarcely described 
in the literature and the significance of this observation 
remains unclear. Perhaps a publication bias has 
Table 5 Expression of SST5C, SST3M and SST2M in relation to disease aggressiveness in PC.
SST expression (number of tumors)
SST5C SST3M SST2M
Patients with recurrent/metastatic disease (n = 7) 5/7 1/7 1/7
Patients died from disease (also included in recurrent/metastatic, n = 5) 4/5 1/5 1/5
Patients with non-recurrent disease (n = 25) 23/25 1/25 1/25
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affected this finding. Previously, Hornick et al. described 
a radioactive-labeled somatostatin analog uptake in the 
cell nucleus of human neuroblastoma cells (39). Some 
researchers have speculated that the antiproliferative and 
apoptotic properties of somatostatin are mediated through 
the protein 86-Ku, which has been shown to function as 
a somatostatin receptor. Binding of somatostatin to 86-Ku 
promotes the translocation of 86-Ku from the cytoplasm 
to the nucleus (40, 41). It is possible, however speculative, 
that the nuclear SST expression described here represents 
a cross-reaction between SST antibodies and 86-Ku.
No standardized scoring system for the 
immunohistochemical evaluation of SSTs currently exists. 
The scoring system used by Körner et al. (42) (examining 
SST2, in particular) yielded a strong correlation with the 
binding of the somatostatin receptor measured using 
in vitro receptor autoradiography. This was, however, 
primarily focused on membrane expression, which 
was marginally prevalent in our tumor samples. Specht 
et  al. compared three different scoring systems on the 
SST expression in bronchopulmonary neoplasms: the 
immunoreactive score (IRS) originally developed for 
the evaluation of estrogen and progesterone receptors 
in breast cancer, the Her2/neu score developed for the 
evaluation of HER expression in breast cancer and the 
hormone receptor score (H score). These scoring systems 
were compared to the results obtained using real-time 
PCR, whereby all showed some correlation, although the 
IRS scoring system emerged with the strongest correlation 
to the RT-PCR results (43). All of these scoring systems rely 
on the percentage of stained cells in combination with 
the staining intensity. In our study, the intensity of the 
stained spots was generally weak and the percentage of 
stained cells was low, particularly regarding the nuclear 
expression. Analyses using either a higher cut-off point 
(counting weakly positive spots scored 1 as negative) or 
a minimum of 10% stained cells for positivity yielded 
insignificant results and the number of positive tumors 
decreased considerably. A cut-off point of 10% to be 
considered positive has been suggested for staining of SST2 
(25); however, there is no consensus on the matter, as also 
a small number of receptor-positive tumor cells might be 
biologically and/or clinically relevant (42). A cut-off point 
as low as 1% has been used regarding other markers, such 
as PDL-1 (44). The actual or clinical significance of the 
weakly stained spots can be questioned. A higher staining 
dilution might further weed out false-positive spots. While 
the PPV for cytoplasmic SST5 is only 0.52, slightly better 
than chance, the NPV is 0.94. According to Juhlin et al., 
the NPV of negative parafibromin staining is also around 
this magnitude (18). This suggests that a negative staining 
for cytoplasmic SST5 strongly indicates a benign tumor.
In general, SSTs represent potential targets for imaging 
and the treatment of NETs. Occasional case studies indicate 
that octreotide might affect PTH-associated hypercalcemia 
and reduce the urinary calcium output in primary 
hyperparathyroidism (45). For instance, Karacavus et  al. 
published a case report of a SST1-positive parathyroid 
adenoma discovered on an octreotide scintigraphy (46). 
Long-acting octreotide has been proposed as a possible 
treatment for PHPT due to adenoma in MEN1 patients. 
Furthermore, somatostatin analogs have been tested in 
the treatment of hyperparathyroidism alongside surgery 
without an apparent effect on the patients’ serum 
calcium or PTH levels (20, 47, 48). Because PCs are so 
rare, parathyroid adenomas have primarily been used in 
these studies.
Among all SSTs, SST2 stands as the most commonly 
expressed throughout the body. In clinical settings, the 
most commonly used somatostatin analogs, such as 
octreotide and lanreotide, target SST2 in particular, and 
also share a certain affinity with SST5. Newer somatostatin 
analogs such as pasireotide and somatoprim have affinity 
for all receptor subtypes, although SST4 to a lesser extent 
(20). Presumably, membranous expression stands as a 
prerequisite for successful treatment or for imaging using 
octreotide or other somatostatin analogs. In our study, 
membrane expression was scarce and did not significantly 
differ between the tumor groups. However, the two SST2 
and SST3 membrane-positive tumors were malignant; 
and we were particularly interested in these receptors 
due to the clinical significance of membrane positivity. 
We found that among the five patients who died of 
PC-related causes, one was SST2M positive and another 
was SST3M positive, indicating that these tumors might 
be more aggressive than their negative counterparts. New 
treatment options could have proved useful in these 
cases. Moreover, further research is necessary in order 
to conclude whether somatostatin analogs targeting 
these receptors could be used to treat membranous SST-
positive PC tumors. In patients with metastatic disease 
not responding to conventional treatment, it may be 
possible to examine the expression of SST2M and SST3M 
for individually customized targeted treatment using 
somatostatin analogs.
PC is one of the rarest carcinomas known, making 
it difficult to study and treat. We studied a nationwide 
cohort (n = 32). The number of carcinomas studied was 
relatively small and our findings warrant validation in 
other cohorts. TMAs are not considered representative 
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of the tissue as a whole. This was taken into account by 
taking several punches from each tumor, both from the 
middle and from the borders of the tumors. Our results 
are consistent, and our statistically significant findings 
follow a gradient with the highest SST expression in PCs 
without exception.
Conclusions
Using immunohistochemistry, we demonstrate that 
SST1–5 are expressed in parathyroid tumors, either in 
the cytoplasm or the nucleus. The expression profiles of 
SST2–5 differ significantly between benign, atypical and 
malignant parathyroid tumors. Additionally, due to the 
large differences in expression between the tumor groups, 
SST5 represents a potential new immunohistochemistry 
panel marker for PC in addition to the established markers 
parafibromin and Ki-67 and suggested markers galectin 3 
and PGP9.5.
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